Search





Search





Markets
/
Stocks
/
srzn
/

Surrozen Inc

SRZN

Add to Watchlist

21.170USD

-0.550-2.53%

Close 07-23 16:00（ET）Quotes delayed by 15 min

206.94MMarket Cap

LossP/E TTM

Surrozen Inc

21.170

-0.550-2.53%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-2.53%

5 Days

+2.02%

1 Month

-14.84%

6 Months

+8.04%

Year to Date

-6.33%

1 Year

+143.96%

Key Figures

21.590Open

21.790High

65.87KVolume

LossP/E TTM

LossP/E Dynamic

--Dividend TTM

0.67%Turnover Ratio

21.720Prev. Close

21.000Low

1.02MTurnover

LossP/E Static

-1.10P/B

0.00%Div Yield TTM

-290.88%ROA

35.00052wk High

0.37Volume Ratio

-63.56MNet Profit

9.78MShares

-36.5766EPS TTM

0.52Beta

-62.80%ROE

7.60052wk Low

3.64%Amplitude

100.00%Gross Margin

206.94MMarket Cap

-2.48Reward/Risk

4.94%Risk Rate

TradingKey Stock Score of Surrozen Inc

Currency: USD Updated: 2026-07-23

Key Insights

Surrozen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Surrozen Inc's Score

Industry at a Glance

Industry Ranking

29 / 386

Overall Ranking

83 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Surrozen Inc Highlights

StrengthsRisks

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.48M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 3.48M.

Fairly Valued

The company’s latest PE is -0.58, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 10.96M shares, increasing 15.48% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.67.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

42.667

Target Price

+85.59%

Upside Space

Surrozen Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 5 analysts

Buy

Current Rating

42.667

Target Price

+85.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

495

Total

Median

Average

Company name

Ratings

Analysts

Surrozen Inc

SRZN

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

Insmed Inc

INSM

...

Indicators

Indicators

Sell(5)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.155

Sell

RSI(14)

38.741

Neutral

STOCH(KDJ)(9,3,3)

42.071

Neutral

ATR(14)

1.796

High Vlolatility

CCI(14)

-101.928

Sell

Williams %R

77.893

Sell

TRIX(12,20)

-0.472

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

21.998

Sell

MA10

22.041

Sell

MA20

23.266

Sell

MA50

24.363

Sell

MA100

26.585

Sell

MA200

22.619

Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Surrozen Inc Info

Ticker SymbolSRZN

CompanySurrozen Inc

CEOParker (Craig C)

Websitehttps://www.surrozen.com

Shareholders

Shareholders

Proportion

The Column Group LP

19.48%

TCG Crossover Management, LLC

12.82%

Millennium Management LLC

6.21%

VR Adviser, LLC

5.45%

StemPoint Capital LP

5.34%

Other

50.69%

Popular Instruments

FAQs

What is the current price of Surrozen Inc (SRZN)?



The current price of Surrozen Inc (SRZN) is 21.17.

What is the symbol of Surrozen Inc?



The ticker symbol of Surrozen Inc is SRZN.

What is the 52-week high of Surrozen Inc?



The 52-week high of Surrozen Inc is 35.00.

What is the 52-week low of Surrozen Inc?



The 52-week low of Surrozen Inc is 7.60.

What is the market capitalization of Surrozen Inc?



The market capitalization of Surrozen Inc is 206.94M.

Is Surrozen Inc (SRZN) currently rated as Buy, Hold, or Sell?



According to analysts, Surrozen Inc (SRZN) has an overall rating of Buy, with a price target of 42.67.

What is the Earnings Per Share (EPS TTM) of Surrozen Inc (SRZN)?



The Earnings Per Share (EPS TTM) of Surrozen Inc (SRZN) is -32.37.